View Older Stories View More Recent Stories
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.4 puts into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1 put into quarter results
-
Eli Lilly & Co. (LLY) call put ratio 1 call to 1.5 puts with into quarter results
-
FDA grants Lilly's olomorasib breakthrough therapy status for pancreatic cancer
-
U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
-
Eli Lilly and Resilience to invest $750 million in US manufacturing
-
Lilly to file for next-gen obesity drug approval in early 2027
-
Novo Nordisk sues Eli Lilly over weight-loss drug ads
-
H.C. Wainwright Downgrades AtaiBeckley Inc (ATAI) to Neutral
-
UBS Reiterates Buy Rating on Eli Lilly (LLY) on Deal to Acquire ATAI
-
Oppenheimer on AtaiBeckley Inc (ATAI): 'LLY Acquisition Validates Psychedelic Advantages'
-
Lilly Said To Near Deal For Psychedelic Drugmaker Ataibeckley - Bloomberg
-
Lilly’s Retevmo approved by FDA for RET Tumors
-
Eli Lilly (LLY) PT Raised to $1,385 at Bernstein SocGen Group
-
Teva lawsuit against Eli Lilly over Forteo revived by appeals court
-
Eli Lilly (LLY) PT Raised to $1,273 at Guggenheim
-
Lilly to present 16 Alzheimer's abstracts at AAIC 2026 in London
-
Eli Lilly: Q2 2026 IPR&D charge estimated at $3.02 per share on GAAP and non-GAAP basis
-
Eli Lilly (LLY) PT Raised to $1,370 at Truist Securities
-
Eli Lilly (LLY) PT Raised to $1,350 at Cantor Fitzgerald as Strong Q2 Results Likely
-
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
-
RBC Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
Innovent and Lilly strike China deal for breast cancer drug
-
FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
-
FDA selects 7 companies for domestic drug manufacturing pilot
-
Sandoz submits generic obesity drug applications to FDA
-
Eli Lilly plans European weight-loss pill launch by early 2027
-
Sangamo files Chapter 11, agrees to sell assets to Lilly, Astellas
-
Eli Lilly & Co. (LLY) Declares $1.73 Quarterly Dividend; 0.6% Yield
-
This digital health stock is ready to re-rate higher: Goldman
-
Eli Lilly (LLY) Reiterated at Overweight by Cantor Fitzgerald as Injectable Obesity TRx Down
-
Oral Wegovy reaches 33% of total prescriptions by May
-
Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
-
BMO Capital on Eli Lilly (LLY): 'Early Data for AJ1-11095 Impress at EHA'
-
Lilly's Jaypirca reduces disease progression risk by 45% in CLL study
-
Leerink highlights drug demand rebound after Memorial Day
-
Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
-
Lilly's oral diabetes drug outperforms rival in late-stage trials
-
Bernstein SocGen Reiterates Outperform Rating on Eli Lilly (LLY)
-
Truist on Eli Lilly (LLY): 'We see near-term and longer-term areas for growth'
-
Lilly reports weight loss data for Foundayo across menopause stages
-
Eli Lilly reports positive results for obesity drug retatrutide trials
-
Morgan Stanley on Eli Lilly (LLY): 'We see ~7% upside to '26 M+Z ests'
-
TD Cowen raises global GLP-1 sales forecast to $150B by 2030
-
ADA 2026 preview: All eyes on these 2 stocks
-
Weight Watchers integrates with Eli Lilly's LillyDirect platform
-
Lilly cuts Germany investment plan in half over healthcare reforms
-
Lilly to present hematology data at European meeting in Stockholm
-
Camurus (CAMX) announces expansion of Lilly collaboration, decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal technology
-
Lilly's Retevmo reduces cancer recurrence risk by 83% in trial
